Explore

Rapid Read Rapid Read
SonoThera's Gene Delivery Technology Shows Promise in Hemophilia A Treatment

SonoThera's Gene Delivery Technology Shows Promise in Hemophilia A Treatment

SonoThera has presented new data at the 67th American Society of Hematology Annual Meeting, demonstrating the effectiveness of its ultrasound-mediated gene delivery technology, RIPPLE™, in treating Hemophilia A. The technology enables the delivery of DNA expression vectors to the liver, resulting in up to 65% of normal Factor VIII protein expression in non-human primate models. This nonviral, non-invasive approach allows for broad, targeted biodistribution of genetic medicines, offering a potential solution to the limitations of current therapies, such as variable expression and immunogenicity.
Trendline Trendline
cGMP Manufacturing Market Expands with Biopharmaceutical Advancements

cGMP Manufacturing Market Expands with Biopharmaceutical Advancements

cGMP Manufacturing Market Expands with Biopharmaceutical Advancements
Rapid Read Rapid Read
Chronotherapy in Cancer Treatment: Timing Drug Delivery to Boost Survival Rates

Chronotherapy in Cancer Treatment: Timing Drug Delivery to Boost Survival Rates

Recent research suggests that timing the administration of cancer drugs according to patients' circadian rhythms could significantly improve treatment outcomes. Studies have shown that administering immunotherapy drugs in the morning, when immune T-cells are more active, can enhance their effectiveness. A study involving patients with non-small cell lung cancer (NSCLC) found that those receiving treatment before 11:30 am had nearly double the survival rate compared to those treated later in the day. This approach, known as chronotherapy, leverages the body's internal clock to optimize drug efficacy and minimize side effects.
Trendline Trendline
Avant Technologies and Austrianova Develop α-Klotho Cell Therapy Following Mayo Clinic Study on Cardiovascular Health

Avant Technologies and Austrianova Develop α-Klotho Cell Therapy Following Mayo Clinic Study on Cardiovascular Health

Avant Technologies and Austrianova Develop α-Klotho Cell Therapy Following Mayo Clinic Study on Cardiovascular Health
Rapid Read Rapid Read
Dr. Sunny Bhatia Honored as One of Modern Healthcare's 100 Most Influential People in Healthcare for 2025

Dr. Sunny Bhatia Honored as One of Modern Healthcare's 100 Most Influential People in Healthcare for 2025

Dr. Sunny Bhatia, President and Chief Medical Officer of Prime Healthcare, has been recognized by Modern Healthcare as one of the 100 Most Influential People in Healthcare for 2025. This accolade highlights individuals who have significantly impacted the healthcare industry through leadership and innovation. Dr. Bhatia, the first System President and Chief Medical Officer in Prime Healthcare's history, oversees a network of 51 hospitals and over 360 outpatient locations across 14 states. Under his leadership, Prime Healthcare completed a major acquisition of eight hospitals in Illinois, ensuring their continued operation and contributing to local economies. Dr. Bhatia has also spearheaded initiatives to integrate advanced technologies, such as AI-enabled workflows and digital tools, to enhance patient care and support clinicians.
Rapid Read Rapid Read
Cellarity Showcases Cell State-Correcting Therapies at Hematology Meeting

Cellarity Showcases Cell State-Correcting Therapies at Hematology Meeting

Cellarity, a biotechnology company, presented new preclinical data on its cell state-correcting therapies for sickle cell disease (SCD) and myelofibrosis at the American Society of Hematology Annual Meeting. The company's platform uses advanced transcriptomics and AI to discover new biological pathways and develop novel therapeutics. Their lead asset, CLY-124, is in phase 1 clinical development for SCD, showing potential to transform standard care by inducing fetal hemoglobin without cytotoxicity. Additionally, Cellarity is advancing a preclinical program targeting myelofibrosis, focusing on selective pathways to avoid common side effects.
Rapid Read Rapid Read
CRISPR Technology Advances Personalized Treatments for Rare Diseases

CRISPR Technology Advances Personalized Treatments for Rare Diseases

CRISPR gene-editing technology is making strides in treating rare diseases, with the first personalized CRISPR therapy successfully administered to a child with a rare genetic disorder. This breakthrough demonstrates the potential of custom gene-editing treatments to address specific mutations, offering hope for individuals with rare disorders. The federal government has announced funding programs to support personalized treatments, aiming to make CRISPR technology accessible to those in need. The FDA is also working to streamline approval processes for personalized therapies, inspired by the success of recent treatments.
Rapid Read Rapid Read
New DNA Editing Therapy Shows Promise in Treating Incurable Leukemia

New DNA Editing Therapy Shows Promise in Treating Incurable Leukemia

Researchers at University College London and Great Ormond Street Hospital have developed a groundbreaking treatment for T-cell acute lymphoblastic leukemia using a technology called base editing. This therapy involves editing the DNA in white blood cells to create a 'living drug' capable of fighting aggressive blood cancers. The treatment has shown remarkable success, with 64% of patients achieving remission. The therapy is particularly significant for patients who have not responded to traditional treatments like chemotherapy and bone marrow transplants. The process involves modifying healthy T-cells from a donor to target and destroy cancerous T-cells without harming the patient's body.
Rapid Read Rapid Read
CRISPR Gene Editing Shows Promise in Reversing Incurable Leukemia

CRISPR Gene Editing Shows Promise in Reversing Incurable Leukemia

A groundbreaking therapy using CRISPR gene editing has shown success in reversing aggressive and previously incurable blood cancers in some patients. The treatment involves editing the DNA in white blood cells to transform them into a cancer-fighting 'living drug.' This innovative approach has been applied to patients with T-cell acute lymphoblastic leukemia, a condition where T-cells grow uncontrollably. The therapy, which was once considered science fiction, has led to remission in nearly two-thirds of the treated patients. The process involves multiple genetic modifications to T-cells, enabling them to target and destroy cancerous cells without harming healthy ones. The study, conducted by University College London and Great Ormond Street Hospital, has been published in the New England Journal of Medicine.
Rapid Read Rapid Read
French Genomic Pathway Managers Enhance Genomic Medicine Care Pathways

French Genomic Pathway Managers Enhance Genomic Medicine Care Pathways

The French Genomic Medicine Initiative (PFMG2025) is advancing genomic medicine by making clinical genome sequencing (GS) more accessible across France. This initiative includes the creation of two national GS laboratories and the integration of digital tools for e-prescription. A key innovation is the introduction of Genomic Pathway Managers (GPMs), a new role designed to bridge clinical practice and operational care pathways. GPMs assist in prescribing GS analyses, coordinating sampling processes, and managing multidisciplinary meetings. A recent study assessed the role of GPMs, revealing their significant involvement in data entry, multidisciplinary meetings, and clinician training. Despite high job satisfaction, challenges such as geographical disparities and the need for role standardization persist.
Rapid Read Rapid Read
CRISPR Technology Faces Regulatory Challenges Amidst Potential for Food Security

CRISPR Technology Faces Regulatory Challenges Amidst Potential for Food Security

CRISPR technology, a precise gene-editing tool, is being explored for its potential to enhance food security by making crops more resilient to environmental stresses such as drought, heat, and disease. The technology is also being used to improve the nutritional value of crops by adding vitamins and essential amino acids. Despite its potential, CRISPR faces significant skepticism from regulators and NGOs due to safety concerns and fears of industry dominance through patenting. The European Union has recently eased regulations on CRISPR plants, exempting many from GMO regulations, which may influence global regulatory perspectives.
Rapid Read Rapid Read
Pete November Honored as Influential Leader in Healthcare

Pete November Honored as Influential Leader in Healthcare

Pete November, President and CEO of Ochsner Health, has been recognized by Modern Healthcare as one of the 100 Most Influential People in Healthcare for 2025. This accolade highlights his leadership and impact within the healthcare industry. Under November's guidance, Ochsner Health has focused on advancing healthcare innovation, enhancing team member experiences, and advocating for high-quality, patient-centric care. His leadership has been pivotal in driving Ochsner's mission to improve community health across the Gulf South. November's strategic vision and commitment to supporting Ochsner's teams have been instrumental in the organization's success and influence in the healthcare sector.